Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan led to greater improvements in hemoglobin compared with eculizumab among patients with paroxysmal ...

Clone size and symptom burden dictate how often patients with PNH require follow-up. Hematology assessments during routine visits should include flow cytometry, CBC, D-dimer levels, and serum ferritin ...

Post hoc analyses of the phase 3 PEGASUS trial found that clinical and hematological improvements were associated with better patient-reported fatigue and physical function outcomes in paroxysmal ...

To help manage the symptoms — from fatigue and headache to bruising and bleeding — of this rare blood disease, follow these steps. “With good care and the right medicines, your PNH can be managed,” ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Patients with paroxysmal nocturnal hemoglobinuria who received iptacopan vs. standard therapy had ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, progressive, multi-system, life-threatening disease, and diagnosing it early in the clinical course is essential for optimizing management ...

BOSTON, April 5, 2011 (GLOBE NEWSWIRE) -- Oncology Care Live (www.OncologyCarelive.com ), the live online oncology congress, today announced that Michael J. Borowitz ...

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Paroxysmal Nocturnal Hemoglobinuria pipeline constitutes 20+ key companies continuously working towards developing 25+ ...

AJMC ®: Paroxysmal nocturnal hemoglobinuria (PNH) is 1 of several complement-driven diseases. Can you describe its clinical presentation? DE CASTRO: PNH presents heterogeneously. One of the 3 ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hemoglobinuria-Pipeline Insights, 2016" drug pipelines to their offering. Hemoglobinuria - Pipeline Insights, 2016 ...